TREX1 and neoplasm: Thus, active therapy with agents that enhance endogenous tumor cGAMP production either through non-specific DNA damage (chemotherapy or radiation) or more targeted approaches such as TREX1 or ENPP1 inhibition, are likely to prime even more robust vascular activation, T cell recruitment and infiltration in the TME.